Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high-versus lower-risk rheumatoid arthritis patients

Arthritis Care and Research

Volumn 64, Issue 10, 2012, Pages 1480-1489

  Curtis, Jeffrey R ^a   Xie, Fenglong ^a   Chen, Lang ^a   Muntner, Paul ^a   Grijalva, Carlos G ^b   Spettell, Claire ^c   Fernandes, Joaquim ^c   McMahan, Raechele M ^c   Baddley, John W ^a   Saag, Kenneth G ^a   Beukelman, Timothy ^a   Delzell, Elizabeth ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c AETNA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; AGE; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; INFECTION; INFECTION RATE; INFECTION RISK SCORE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRIVATE HEALTH INSURANCE; PROGNOSIS; RHEUMATOID ARTHRITIS; SERIOUS INFECTION; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INFECTION; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869160661     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21805     Document Type: Article

References (38)

1. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor-antagonists. Arthritis Rheum 2007; 56: 1125-33. (Pubitemid 46608637)
2. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66: 1339-44. (Pubitemid 47492478)
3. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-agents. JAMA 2009; 301: 737-44.
4. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12. (Pubitemid 41612206)
5. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford) 2010; 49: 82-90.
6. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85. (Pubitemid 43736578)
7. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-9.
8. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation 2010; 121: 1768-77.
9. Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011; 70: 1401-6.
10. Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, et al. Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf 2011; 20: 1199-209.
11. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20. (Pubitemid 37323253)
12. Patkar NM, Curtis JR, Teng GG, Allison JJ, Saag M, Martin C, et al. Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol 2009; 62: 321-7.
13. Miettinen OS. Stratification by a multivariate confounder score. Am J Epidemiol 1976; 104: 609-20. (Pubitemid 8007913)
14. Cadarette SM, Gagne JJ, Solomon DH, Katz JN, Sturmer T. Confounder summary scores when comparing the effects of multiple drug exposures. Pharmacoepidemiol Drug Saf 2010; 19: 2-9.
15. Sturmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 2005; 161: 891-8. (Pubitemid 40577844)
16. WHO Fracture Risk Assessment Tool. URL: http://shef.ac.uk/ FRAX.
17. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47. (Pubitemid 28213628)
18. Arbogast PG, Ray WA. Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders. Am J Epidemiol 2011; 174: 613-20.
19. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294-300.
20. Brookhart MA, Patrick AR, Dormuth C, Avorn J, Shrank W, Cadarette SM, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007; 166: 348-54. (Pubitemid 47216808)
21. Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in patients with pneumonia outside "flu" season: pleiotropic benefits or residual confounding? Am J Respir Crit Care Med 2008; 178: 527-33.
22. Glynn RJ, Knight EL, Levin R, Avorn J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 2001; 12: 682-9. (Pubitemid 33134531)
23. Gonen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika 2005; 92: 965-70. (Pubitemid 41681247)
24. Lemeshow S, Hosmer JD. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982; 115: 92-106. (Pubitemid 12205725)
25. Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006; 59: 437-47.
26. Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 2005; 58: 550-9. (Pubitemid 40692720)
27. Perkins S, Tu W, Underhill M, Zhou X, Murray M. The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 2000; 9: 93-101. (Pubitemid 30307349)
28. Cleveland W. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979; 74: 829-36.
29. White H. A heteroskedasticity-consistent covariace matrix estimator and a direct test for heteroscedasticity. Econometrica 1980; 48: 817-30.
30. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50: 124-31.
31. Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C. Drugspecific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor-antagonists [letter]. Arthritis Rheum 2007; 56: 4226-7. (Pubitemid 350262351)
32. Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of nontuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70: 616-23.
33. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
34. Manno RL, Calabrese LH, Curtis JR, Cush JJ, Bingham CC III. Evaluating immunization knowledge and practices by rheumatologists [abstract]. Arthritis Rheum 2008; 58: 4007.
35. Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010; 40: 2-14e1.
36. Li CY, Sung FC. A review of the healthy worker effect in occupational epidemiology. Occup Med (Lond) 1999; 49: 225-9.
37. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914-20.
38. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al, on behalf of the British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor-therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56: 2896-904.